We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Despite Short-Term Costs, Guidant Acquisition Seen as Boon to Abbott
Despite Short-Term Costs, Guidant Acquisition Seen as Boon to Abbott
July 21, 2006
Analysts are projecting a sunny outlook for Abbott Laboratories based on 2006 second-quarter results — despite some company challenges.
At first glance, the company may seem to be faring worse than it actually is, said stock market website www.SeekingAlpha.com Editor Jonathan Liss.